NCT05779579 - Study of HS-10517 in Chinese Adult Participants | Biotech Hunter

Enrollment

340

Participants

Timeline

Start Date

February 1, 2023

Primary Completion Date

May 31, 2023

Study Completion Date

June 30, 2023

Conditions

COVID-19

Interventions

DRUG

HS-10517 Dose 1

HS-10517 Dose 1+Ritonavir

DRUG

HS-10517 Dose 2

HS-10517 Dose 2+Ritonavir

DRUG

HS-10517 Dose 3

HS-10517 Dose 3+Ritonavir

DRUG

HS-10517 Dose 4

HS-10517 Dose 4+Ritonavir

DRUG

Placebo

Dose level A of placebo

Trial Locations (1)

RECRUITING

The First Affiliated Hospital of Shandong First Medical University Shandong Provincial Qianfoshan Hospital, Jinan